U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
139594
Substance Class Protein
Created
by admin
on Sat Dec 16 11:34:04 GMT 2023
Edited
by admin
on Sat Dec 16 11:34:04 GMT 2023
Protein Type RECEPTOR
Protein Sub Type
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
NJ1Q2Q7LO5
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CANNABINOID RECEPTOR 1
Common Name English
CANN6
Common Name English
CNR1
Common Name English
CB1 RECEPTOR
Common Name English
CB1
Common Name English
CNR
Common Name English
CB-1
Common Name English
CB-R
Common Name English
Code System Code Type Description
UNIPROT
P21554
Created by admin on Sat Dec 16 11:34:14 GMT 2023 , Edited by admin on Sat Dec 16 11:34:14 GMT 2023
PRIMARY
PHAROS
P21554
Created by admin on Sat Dec 16 11:34:14 GMT 2023 , Edited by admin on Sat Dec 16 11:34:14 GMT 2023
PRIMARY
FDA UNII
NJ1Q2Q7LO5
Created by admin on Sat Dec 16 11:34:14 GMT 2023 , Edited by admin on Sat Dec 16 11:34:14 GMT 2023
PRIMARY
Glycosylation Type HUMAN
Glycosylation Link Type Site
N 1_77
N 1_83
N 1_112
Related Record Type Details
Structure of NMP-7
AGONIST -> TARGET
Structure of HU-310
AGONIST -> TARGET
Ki
Structure of XLR-11
AGONIST -> TARGET
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
Structure of AB-CHMINACA
AGONIST -> TARGET
Ki
Structure of MDMB-CHMCZCA
AGONIST -> TARGET
EC50
Structure of ZEVAQUENABANT
INHIBITOR -> TARGET
Structure of ANEB-001
INHIBITOR -> TARGET
Structure of APINACA
AGONIST -> TARGET
EC50
Structure of MDMB-FUBICA
AGONIST -> TARGET
Structure of MA-CHMINACA
AGONIST -> TARGET
Ki
Structure of 5F-ADBICA
AGONIST -> TARGET
EC50
Structure of EG-2201
AGONIST -> TARGET
Ki
Structure of ADB-HEXINACA
AGONIST -> TARGET
Structure of JWH-091
LIGAND->TARGET
NIMACIMAB
INHIBITOR -> TARGET
Structure of PB-22
AGONIST -> TARGET
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
Structure of NABILONE
AGONIST -> TARGET
Ki
Structure of DRINABANT
INHIBITOR -> TARGET
Structure of 5F-ADB-PINACA
AGONIST -> TARGET
EC50
Structure of SERINOLAMIDE A
AGONIST -> TARGET
Structure of FDU-NNE1
AGONIST -> TARGET
Ki
Structure of AB-FUBINACA 3-FLUOROBENZYL ISOMER
AGONIST -> TARGET
Structure of JWH-080
AGONIST -> TARGET
Ki
Structure of PTI-2
AGONIST -> TARGET
Structure of AM-2201
AGONIST -> TARGET
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
Structure of ADB-5’Br-PINACA
AGONIST -> TARGET
Structure of CUMYL-CB-MEGACLONE
AGONIST -> TARGET
Structure of 5F-CUMYL-P7AICA
AGONIST -> TARGET
EC50
Structure of MN-18
AGONIST -> TARGET
Ki
Structure of 5-FLUORO-MN-18
AGONIST -> TARGET
Ki
Structure of CUMYL-NBMINACA
AGONIST -> TARGET
Structure of MDMB-BINACA
AGONIST -> TARGET
Structure of ADB-CHMINACA
AGONIST -> TARGET
Ki
Structure of 5-FLUORO-AMB-PICA
AGONIST -> TARGET
Ki
Structure of MO-CHMINAKA
AGONIST -> TARGET
Ki
Structure of UR-144
AGONIST -> TARGET
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
Structure of PTI-3
AGONIST -> TARGET
Structure of SDB-005
AGONIST -> TARGET
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
Structure of RCS-4 C4
WEAK AGONIST->TARGET
EC50
Structure of MCHB-1
AGONIST -> TARGET
Ki
Structure of NE-CHMIMO
AGONIST -> TARGET
Structure of GAT100
NEGATIVE ALLOSTERIC MODULATOR->TARGET
Structure of AB-FUBINACA 2-FLUOROBENZYL ISOMER
AGONIST -> TARGET
Ki
Structure of AMG-1
AGONIST -> TARGET
Structure of Pregnenolone
NEGATIVE ALLOSTERIC MODULATOR (NAM)->TARGET
∆9-tetrahydrocannabinol (THC), substantially increases the synthesis of pregnenolone in the brain via activation of the type-1 cannabinoid (CB1) receptor. Pregnenolone then, acting as a signaling-specific inhibitor of the CB1 receptor, reduces several effects of THC. This negative feedback mediated by pregnenolone reveals a previously unknown paracrine/autocrine loop protecting the brain from CB1 receptor overactivation.
Structure of 5F-ADB
AGONIST -> TARGET
Ki
Structure of AM-679 (CANNABINOID)
AGONIST -> TARGET
Structure of THJ-2201
AGONIST -> TARGET
Ki
Structure of PERROTTETINENE
ACTIVATOR -> TARGET
Structure of AM-4030
AGONIST -> TARGET
Ki
Structure of CP-55940
AGONIST -> TARGET
Strong agonist
EC50
Structure of APP-CHMINACA
AGONIST -> TARGET
Ki
Structure of STS-135
AGONIST -> TARGET
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
Structure of 5-FLUORO-MN-24
AGONIST -> TARGET
Structure of DRONABINOL
AGONIST -> TARGET
EC50
Structure of SGT-151
AGONIST -> TARGET
Structure of AB-PINACA
AGONIST -> TARGET
EC50
Structure of 4F-ABINACA
AGONIST -> TARGET
Structure of APP-FUBINACA
AGONIST -> TARGET
Ki
Structure of PX-1
AGONIST -> TARGET
Ki
Structure of MDMB-4EN-PINACA
AGONIST -> TARGET
Structure of ADBICA
AGONIST -> TARGET
EC50
Structure of AM-404
ACTIVATOR -> TARGET
Inhibits a anandamide selective transport mechanism (reuptake)
Structure of JWH-387
AGONIST -> TARGET
Ki
Structure of Delta-8-Tetrahydrocannabinol
AGONIST -> TARGET
Structure of JHU-75528 C-11
RADIOLIGAND->TARGET
Structure of PF-03550096
AGONIST -> TARGET
Structure of TARANABANT
INVERSE AGONIST->TARGET
Structure of 5F-EMB-PINACA
AGONIST -> TARGET
Structure of ABO-4EN-PINACA
AGONIST -> TARGET
Structure of ADB-BICA
AGONIST -> TARGET
Structure of FUB-JWH-018
AGONIST -> TARGET
Ki
Structure of NESS-040C5
AGONIST -> TARGET
Ki
Structure of AB-002
AGONIST -> TARGET
EC50
Structure of AMB-FUBINACA
AGONIST -> TARGET
Ki
Structure of AMB
AMB
AGONIST -> TARGET
Ki
Structure of 4F-MDMB-BICA
AGONIST -> TARGET
EC50
Structure of JWH-018
AGONIST -> TARGET
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
Structure of CUMYL-PICA
AGONIST -> TARGET
Ki
Structure of 5-FLUORO-AB-PINACA
AGONIST -> TARGET
EC50
Structure of 5F-SDB-003
AGONIST -> TARGET
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
Structure of FAB-144
AGONIST -> TARGET
Structure of AM-11542
AGONIST -> TARGET
Ki
Structure of CUMYL-THPINACA
AGONIST -> TARGET
Ki
Structure of PTI-1
AGONIST -> TARGET
Structure of CP-55940 H-3
RADIOLIGAND->TARGET
Kd
Structure of METHANANDAMIDE, (±)-
AGONIST -> TARGET
Structure of NNL-1
AGONIST -> TARGET
Structure of MMB-018
AGONIST -> TARGET
Structure of ADB-FUBINACA
AGONIST -> TARGET
EC50
Structure of CID-16020046
LIGAND->TARGET
Structure of 5F-SDB-004
AGONIST -> TARGET
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
Structure of 5F-SDB-006
AGONIST -> TARGET
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
Structure of 5F-SDB-002
AGONIST -> TARGET
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
Structure of AM-281
INHIBITOR -> TARGET
AM281 is a selective CB1 receptor antagonis
BINDING
IC50
Structure of 5-FLUORO-AB-PICA, (±)-
AGONIST -> TARGET
EC50
Structure of ADBICA, (±)-
AGONIST -> TARGET
EC50
Structure of MN-24
AGONIST -> TARGET
Structure of ART-2713
AGONIST -> TARGET
Structure of IBIPINABANT
INHIBITOR -> TARGET
Structure of EDMB-4EN-PINACA
AGONIST -> TARGET
Structure of 5-FLUORO-PB-22
AGONIST -> TARGET
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
Structure of EAM-2201
AGONIST -> TARGET
Ki
Structure of RIMONABANT
INVERSE AGONIST->TARGET
Rimonabant was the first CB1r antagonist to be approved for the treatment of obesity in Europe (Van Gaal et al., 2005; Henness et al., 2006). It was withdrawn from the market in 2008 because it was found to cause a significant drug-related risk of serious psychiatric disorders including anxiety and depression (Christensen et al., 2007).
Ki
Structure of WIN-55212-2
AGONIST -> TARGET
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
Structure of THJ-018
AGONIST -> TARGET
Structure of BZO-CHMOXIZID
AGONIST -> TARGET
Emax 99% of CP55940
EC50
Structure of F-2201
AGONIST -> TARGET
Ki
Structure of CANNABIDIOL
INVERSE AGONIST->TARGET
Structure of SDB-004
AGONIST -> TARGET
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
Structure of RCS-3
AGONIST -> TARGET
EC50
Structure of PSB-SB-1202
AGONIST -> TARGET
Structure of MDMB-CHMINACA
AGONIST -> TARGET
Ki
Structure of AB-FUBINACA
AGONIST -> TARGET
EC50
Structure of 5-FLUORO PHENYL-PICA
AGONIST -> TARGET
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
Structure of JD-5037
INVERSE AGONIST->TARGET
Structure of 5-FLUORO-CUMYL-PICA
AGONIST -> TARGET
Ki
Structure of ADB-FUBICA
AGONIST -> TARGET
EC50
Structure of O-774
AGONIST -> TARGET
Very potent cannabinoid effects in animal studies.
Ki
Structure of RCS-4
AGONIST -> TARGET
EC50
Structure of CUMYL-4CN-BINACA
AGONIST -> TARGET
A potent agonist
Structure of CP-55940
INHIBITOR -> TARGET
BINDING
IC50
Structure of MDMB-FUBINACA
AGONIST -> TARGET
EC50
Structure of MK-9740 F-18
RADIOLIGAND->TARGET
IC50
Structure of AB-PICA
AGONIST -> TARGET
EC50
Structure of RCS-2
AGONIST -> TARGET
EC50
Structure of MEPIRAPIM
WEAK AGONIST->TARGET
Ki
Structure of Monlunabant
INHIBITOR -> TARGET
IC50
Structure of NNL-2
AGONIST -> TARGET
Structure of ANANDAMIDE
AGONIST -> TARGET
Natural agonist
Structure of JWH-018
AGONIST -> TARGET
EC50
Structure of ADB-PINACA
AGONIST -> TARGET
EC50
Structure of ROSONABANT
INHIBITOR -> TARGET
Structure of MK-9740
INVERSE AGONIST->TARGET
IC50
Structure of EG-018
AGONIST -> TARGET
Ki
Structure of AB-FUBICA
AGONIST -> TARGET
EC50
Structure of 5-FLUORO-AMP
AGONIST -> TARGET
Ki
Structure of AB-001 (cannabinoid)
AGONIST -> TARGET
EC50
Structure of 4F-MDMB-BINACA
AGONIST -> TARGET
Structure of BIPICANA
AGONIST -> TARGET
Structure of 5F-EDMB-PICA
AGONIST -> TARGET
Structure of APICA
AGONIST -> TARGET
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
Structure of PX-2
AGONIST -> TARGET
Structure of EPM-301
NEGATIVE ALLOSTERIC MODULATOR (NAM)->TARGET
Assumed from CBD and CBDA
Structure of OTENABANT
INHIBITOR -> TARGET
Structure of 5-FLUORO-AB-PICA
INHIBITOR -> TARGET
Ki
Structure of CHO-4'Me-5'Br-FUBOXPYRA
AGONIST -> TARGET
Assumed target and agonist
Structure of AM-679
AGONIST -> TARGET
Structure of 5F-CUMYL-PEGACLONE
AGONIST -> TARGET
5F-CUMYL-PEGACLONE acts as a potent full agonist of the CB1 receptor.
Structure of CBL-018
AGONIST -> TARGET
Structure of ADB-5Br-INACA
AGONIST -> TARGET
Exhibit cannabinoid (CB) receptor activity but overall potency is expected to be low.
Structure of FUBIMINA
AGONIST -> TARGET
Ki
Structure of FMPEP-D2 F-18
RADIOLIGAND->TARGET
Structure of MEPPEP C-11
RADIOLIGAND->TARGET
Ki
Structure of SURINABANT
INHIBITOR -> TARGET
Structure of UR-144 N-5-HYDROXYPENTYL
AGONIST -> TARGET
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
Structure of JWH-307
AGONIST -> TARGET
Structure of KN-387271
AGONIST -> TARGET
Structure of CL-2201
AGONIST -> TARGET
Ki
Structure of N-(2S,3S)-3-ETHYL-3-DIDEMETHYL 5-FLUORO ADB-PINACA
AGONIST -> TARGET
Ki
Structure of SDB-006
AGONIST -> TARGET
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
Structure of AB-BICA
AGONIST -> TARGET
ASSUMED ACTIVITY FROM ANALOGS
Structure of BZODZ-EPYR
AGONIST -> TARGET
Structure of 5-BROMO APINACA
AGONIST -> TARGET
Structure of METHANANDAMIDE
AGONIST -> TARGET
Structure of 5F-MDMB-P7AICA
AGONIST -> TARGET
Emax=142% relative to JWH-018
EC50
Structure of 5F-MDMB-PICA
AGONIST -> TARGET
Potent agonist of both the CB1 receptor and the CB2 receptor.
EC50
Structure of 2-ARACHIDONOYLGLYCEROL
AGONIST -> TARGET
An endogenous agonist
Structure of SDB-003
AGONIST -> TARGET
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
Structure of RIMONABANT
INHIBITOR -> TARGET
Rimonabant (SR141716) is a highly potent, brain penetrated and selective central cannabinoid receptor (CB1) antagonist
BINDING
IC50
Structure of ABO-4EN-PINACA, (±)-
AGONIST -> TARGET
Structure of ADB-FUBIATA
AGONIST -> TARGET
EC50
Structure of 5-CHLORO-AB-PINACA
AGONIST -> TARGET
Ki
Structure of CMX-020
AGONIST -> TARGET
Structure of 5F-CUMYL-PINACA
AGONIST -> TARGET
Structure of DRONABINOL
AGONIST -> TARGET
Mouse AtT-20 neuroblastoma cells stably transfected with human CB1
EC50
Structure of ADB-4EN-PINACA
AGONIST -> TARGET
Structure of MDMB-CHMICA
AGONIST -> TARGET
Ki
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT CHEMICAL
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966